Current strategies to enhance the targeting of polydopamine-based platforms for cancer therapeutics

Applications of polydopaminic nanomaterials in mucosal drug delivery

Polydopamine (PDA) is a biopolymer with unique physicochemical properties, including free-radical scavenging, high photothermal conversion efficiency, biocompatibility, biodegradability, excellent fluorescent and theranostic capacity due to their abundant surface chemistry. Thus, PDA is used for a myriad of applications including drug delivery, biosensing, imaging and cancer therapy. Recent reports present a new functionality of PDA as a coating nanomaterial, with major implications in mucosal drug delivery applications, particularly muco-adhesion and muco-penetration. However, this application has received minimal traction in the literature. In this review, we present the physicochemical and functional properties of PDA and highlight its key biomedical applications, especially in cancer therapy. A detailed presentation of the role of PDA as a promising coating material for nanoparticulate carriers intended for mucosal delivery forms the core aspect of the review. Finally, a reflection on key considerations and challenges in the utilizing PDA for mucosal drug delivery, along with the possibilities of translation to clinical studies is expounded.

Engineering Bio-MOF/polydopamine as a biocompatible targeted theranostic system for synergistic multi-drug chemo-photothermal therapy

In this study, a biodegradable multifunctional photothermal drug delivery nanoparticles (MPH NPs) using curcumin (Cur) as the ligand coated with hyaluronic acid (HA) was successfully prepared, which could simultaneously deliver Cur and doxorubicin hydrochloride (DOX·HCl) to overcome the common drug resistance in cancer cells. Polydopamine (PDA) as a protective shell prevents premature degradation of Cur in physiological environment and enables it to play effective medicinal value. MPH NPs can specifically recognize CD44 receptors on the surface of cancer cells for tumor targeting, with the damage of the partially released DOX to the superficial tumor cells, and then the positively charged Cur released may gradually penetrate into the cells through electron interaction to improve the problem of low permeability. In vitro cell experiments showed that hydrophobic/hydrophilic drugs co-loaded MPDH (MPH loaded with DOX·HCl) could enter the cancer cells through the endocytosis mediated by clathrin / caveolin, and the inhibition rate of MPDH on HeLa cells reached 79.28 % irradiation under 808 nm laser. MPH were composed of safe materials that have been proven to be biodegradable in human body, which avoided the disadvantages that NPs were difficult to discharge and caused damage to normal organs during long-term use.

Melanin and Melanin-Functionalized Nanoparticles as Promising Tools in Cancer Research-A Review

Cancer poses an ongoing global challenge, despite the substantial progress made in the prevention, diagnosis, and treatment of the disease. The existing therapeutic methods remain limited by undesirable outcomes such as systemic toxicity and lack of specificity or long-term efficacy, although innovative alternatives are being continuously investigated. By offering a means for the targeted delivery of therapeutics, nanotechnology (NT) has emerged as a state-of-the-art solution for augmenting the efficiency of currently available cancer therapies while combating their drawbacks. Melanin, a polymeric pigment of natural origin that is widely spread among many living organisms, became a promising candidate for NT-based cancer treatment owing to its unique physicochemical properties (e.g., high biocompatibility, redox behavior, light absorption, chelating ability) and innate antioxidant, photoprotective, anti-inflammatory, and antitumor effects. The latest research on melanin and melanin-like nanoparticles has extended considerably on many fronts, allowing not only efficient cancer treatments via both traditional and modern methods, but also early disease detection and diagnosis. The current paper provides an updated insight into the applicability of melanin in cancer therapy as antitumor agent, molecular target, and delivery nanoplatform.

Construction of a Mesoporous Polydopamine@GO/Cellulose Nanofibril Composite Hydrogel with an Encapsulation Structure for Controllable Drug Release and Toxicity Shielding

The development of intelligent and multifunctional hydrogels having photothermal properties, good mechanical properties, sustained drug release abilities with low burst release, antibacterial properties, and biocompatibility is highly desirable in the biomaterial field. Herein, mesoporous polydopamine (MPDA) nanoparticles wrapped with graphene oxide (GO) were physically cross-linked in cellulose nanofibril (CNF) hydrogel to obtain a novel MPDA@GO/CNF composite hydrogel for controllable drug release. MPDA nanoparticles exhibited a high drug loading ratio (up to 35 wt %) for tetracycline hydrochloride (TH). GO was used to encapsulate MPDA nanoparticles for extending the drug release time and reinforcing the physical strength of the obtained hydrogel. The mechanical strength of the as-fabricated MPDA@GO/CNF composite hydrogel was five times greater compared to that of the pure CNF hydrogel. Drug release experiments demonstrated that burst release behavior was significantly reduced by adding MPDA@GO. The drug release time of the MPDA@GO/CNF composite hydrogel was 3 times and 7.2 times longer than that of the polydopamine/CNF hydrogel and pure CNF hydrogel, respectively. The sustained and controlled drug release behaviors of the composite hydrogel were highly dependent on the proportion of MPDA and GO. Moreover, the rate of drug release could be accelerated by near-infrared (NIR) light irradiation and pH value change. The drug release kinetics of the as-prepared composite hydrogel was well described by the Korsmeyer-Peppas model, and the drug release mechanism of TH from the composite hydrogel was anomalous transport. Importantly, this carefully designed MPDA@GO/CNF composite hydrogel showed good biocompatibility through an in vitro cytotoxicity test. In particular, the toxicity of GO was well shielded by the CNF hydrogel. Therefore, this novel MPDA@GO/CNF composite hydrogel with an encapsulation structure for controllable drug release and toxicity shielding of GO could be used as a very promising controlled drug delivery carrier, which may have potential applications for chemical and physical therapies.